Implementation program for advanced pancreatic cancer care
Official title: Nationwide Implementation Program for Optimal Multidisciplinary Management and Resection of Locally Advanced Pancreatic Cancer (PREOPANC-4)
Run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · NCT05524090 · Data updated 2026-11-12
This program is testing new ways to improve treatment and survival rates for people with locally advanced pancreatic cancer in the Netherlands by using the best practices from around the world.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 223 (estimated) |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Amsterdam, North Holland) |
| Status | Recruiting |
| Started | July 1, 2021 |
| Main results expected | December 31, 2024 |
| Study ends | December 31, 2030 |
| Registry record updated | September 1, 2022 |
| Trial ID | NCT05524090 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this program are adults aged 18 and older with pathology-confirmed locally advanced pancreatic cancer who have shown non-progressive disease after at least four months of systemic chemotherapy.
✕Probably not a fit
Patients with metastatic pancreatic cancer or those with extensive arterial involvement may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This program aims to implement international best practices for the care of locally advanced pancreatic cancer (LAPC) in the Netherlands from 2021 to 2030. It includes a multidisciplinary training initiative involving leading international expert centers to enhance patient selection and treatment outcomes. The focus is on improving the resection rates and five-year survival for LAPC patients through a structured approach to chemotherapy and surgical techniques. The program will evaluate the effectiveness of these practices in a real-world setting.
Why it matters
Potential benefit: If successful, this program could significantly improve survival rates for patients with locally advanced pancreatic cancer by increasing the number of patients eligible for surgery.
How similar studies have gone: Other studies have shown success with similar multidisciplinary approaches in improving outcomes for pancreatic cancer, indicating that this implementation program is building on established practices.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Pathology-confirmed (LAPC)\* * CT-based non-progressive disease (RECIST criteria) after at least 4 months of systemic chemotherapy (\[m\]FOLFIRINOX / gemcitabine-nab-paclitaxel). Exclusion Criteria: * Metastatic pancreatic cancer prior to induction chemotherapy. * According to the Dutch Pancreatic Cancer Group (DPCG) definition: \>90 degrees arterial tumor involvement (i.e. superior mesenteric artery, celiac axis, and/or hepatic artery) and/or portovenous involvement of either \>270 degrees or occlusion.
Where it's running
-
Amsterdam UMC, locatie AMC
Amsterdam, North Holland, Netherlands Recruiting
Study contacts
- Principal investigator: Marc G Besselink, MD, MSc, PhD — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Study coordinator: Thomas F Stoop, MD
- Email: t.f.stoop@amsterdamUMC.nl
- Phone: +316 547 555 11
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PTM-101 treatment for pancreatic cancer
This study is testing a new treatment called PTM-101 combined with chemotherapy to see if it can help people with certain types of pancreatic cancer who haven't had treatment before.
-
Assessing survival and quality of life in patients with advanced pancreatic cancer
This study looks at how long people with advanced pancreatic cancer live and how their quality of life is affected while being treated at different hospitals in the Nordic region.
-
Combining Gemcitabine and Celecoxib for Pancreatic Cancer Treatment
This study is testing if adding celecoxib to gemcitabine can help people who have had surgery for pancreatic cancer live longer and stay cancer-free.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.